ClinicalTrials.gg

Program

Prednisone

Also written as “prednisone”, “CHOP” and “Lodotra®”.

Its studies are mostly in Prostatic Neoplasms · Lymphoma, Large B-Cell, Diffuse · Arthritis, Rheumatoid · Lymphoma, T-Cell, Peripheral · Asthma, led by 13 companies.

Furthest: phase 4, since Nov 1, 199926 company-led studies, 3 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer40 open or runningphase 3since Nov 1, 1999Nov 1, 1999none ahead
Sanofi40 open or runningphase 4since Jul 20, 2012Mar 3, 2011none ahead
Bristol-Myers Squibb30 open or runningphase 2since Apr 19, 2007Apr 19, 2007none ahead
Takeda31 open or runningphase 3since Jul 25, 2007Jul 25, 2007none ahead
Boehringer Ingelheim20 open or runningphase 4since Jul 8, 2014Jul 8, 2014none ahead
Eli Lilly21 open or runningphase 2since May 11, 2020May 11, 2020Feb 2027phase 2 · NCT04411654
Mundipharma20 open or runningphase 4since Feb 14, 2014Mar 14, 2013none ahead
Amgen10 open or runningphase 2since May 26, 2008May 26, 2008none ahead
ampel-biosolutions-llc10 open or runningphase 4since Mar 21, 2017Mar 21, 2017none ahead
caredx11 open or runningno phasesince Oct 21, 2026Oct 21, 2026Dec 2028NCT07905599
Ionis Pharmaceuticals10 open or runningphase 2since Nov 2, 2010Nov 2, 2010none ahead
Oncotherapeutics10 open or runningphase 2since Jul 30, 2014Jul 30, 2014none ahead
Sumitomo Pharma10 open or runningphase 1since Dec 7, 2020Dec 7, 2020none ahead

Also a collaborator on its studies: AbbVie, basilea-pharmaceutica-international-ltd and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Nov 1, 1999.

  1. Feb 14, 2014Phase 4 study in Arthritis, RheumatoidMundipharma · NCT02072200 · 147 enrolled · Korea, Republic of
  2. Feb 26, 2014Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02074137 · 10 enrolled · India
  3. Jul 8, 2014Boehringer Ingelheim's first study: phase 4 study in HIV InfectionsNew to Boehringer IngelheimBoehringer Ingelheim · NCT02184299 · 138 enrolled
  4. Jul 30, 2014Oncotherapeutics's first study: phase 2 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT02206425 · 45 enrolled · United States
  5. Oct 16, 2014Phase 1 study in HealthyBoehringer Ingelheim · NCT02268149 · 20 enrolled
  6. Apr 21, 2016Phase 1 study in Healthy AdultsPfizer · NCT02767089 · 37 enrolled · United States
  7. May 4, 2016Phase 2 study in Carcinoma, Renal CellBristol-Myers Squibb · NCT02763761 · United States
  8. Dec 22, 2016Phase 2 study in Lymphoma, Large B-Cell, DiffuseBristol-Myers Squibb · NCT03003520 · 46 enrolled · United States, Austria, Denmark and more
  9. Mar 21, 2017ampel-biosolutions-llc's first study: phase 4 study in Lupus Erythematosus, SystemicNew to ampel-biosolutions-llcampel-biosolutions-llc · NCT03098823 · 62 enrolled · United States
  10. May 11, 2020Eli Lilly's first study: phase 2 study in Gaucher DiseaseNew to Eli LillyEli Lilly · NCT04411654 · 7 enrolled · United States, United Kingdom
  11. Dec 7, 2020Sumitomo Pharma's first study: phase 1 study in Metastatic Castration-Resistant Prostate CancerNew to Sumitomo PharmaSumitomo Pharma · NCT04666129 · 48 enrolled · United States
  12. Jan 4, 2023Phase 2 study in LymphomaTakeda · NCT05673785 · 52 enrolled · China
  13. Nov 1, 2023Phase 1 study in Dermatitis, AtopicEli Lilly · NCT06119529 · 18 enrolled · United States
  14. Oct 21, 2026caredx's first study: no phase study in Heart Transplant RejectionNew to caredxcaredx · NCT07905599 · 200 planned

Ahead

  1. Feb 2027Primary completion: phase 2 study in Gaucher DiseaseEli Lilly · NCT04411654
  2. Dec 2028Primary completion: no phase study in Heart Transplant Rejectioncaredx · NCT07905599

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
vamorolonerulereveragen-biopharma-incphase 411
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07905599Heart Transplant Rejection–Not yet recruitingcaredxDec 2028200
NCT06119529Dermatitis, Atopic · United States1TerminatedEli LillyApr 8, 202418
NCT05673785Lymphoma · China2Active, not recruitingTakedaApr 27, 202552
NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States1CompletedSumitomo PharmaMay 28, 202448
NCT04411654Gaucher Disease · United States, United Kingdom2Active, not recruitingEli LillyFeb 20277
NCT03098823Lupus Erythematosus, Systemic · United States4Completedampel-biosolutions-llcMay 28, 201962
NCT03003520Lymphoma, Large B-Cell, Diffuse · United States, Austria, Denmark and more2CompletedBristol-Myers SquibbApr 24, 202246
NCT02763761Carcinoma, Renal Cell · United States2WithdrawnBristol-Myers SquibbMar 31, 20170
NCT02767089Healthy Adults · United States1CompletedPfizerMar 200637
NCT02268149Healthy1CompletedBoehringer IngelheimJul 200020
NCT02206425Multiple Myeloma · United States2CompletedOncotherapeuticsJan 19, 201845
NCT02184299HIV Infections4CompletedBoehringer IngelheimJan 2000138
NCT02074137Prostate Cancer Metastatic · India4CompletedSanofiMar 201610
NCT02072200Arthritis, Rheumatoid · Korea, Republic of4CompletedMundipharmaApr 2015147
NCT01821040Polymyalgia Rheumatica · United Kingdom3TerminatedMundipharmaApr 201462
NCT01649635Prostatic Neoplasms · Brazil4CompletedSanofiJan 201445
NCT01511536Prostatic Neoplasms · United States, France, United Kingdom2CompletedSanofiJul 201438
NCT01393639Arthritis, Rheumatoid · United States, Bulgaria, Colombia and more2CompletedPfizerJun 3, 2014323
NCT01308580Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedSanofiAug 20151,200
NCT01234025Castrate-Resistant Prostate Cancer · United States, Hungary, Poland and more2CompletedIonis PharmaceuticalsMay 2013113
NCT00715208Lymphoma, Follicular · United States, Puerto Rico2CompletedTakedaFeb 201155
NCT00686335Asthma · France2CompletedAmgenMar 201012
NCT00507416Multiple Myeloma · United States, Puerto Rico3CompletedTakedaMar 2013502
NCT00463385Primary Myelofibrosis · United States, Austria, Italy and more2CompletedBristol-Myers SquibbMay 1, 200988
NCT00004071Prostatic Neoplasms · United States3CompletedPfizerSep 2007
NCT00003343Prostatic Neoplasms · United States3CompletedPfizerJan 2001525

How it is read

Names in the registry

  • “Prednisone”, 39 entries
  • “prednisone”, 7 entries
  • “CHOP”, 2 entries
  • “Lodotra®”, 2 entries
  • “Abiraterone/prednisone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.